Drugs / Y-90-Zevalin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01510184 | Apr 2012 → Oct 2014 | diffuse large B-cell lymphoma, follicular lymphoma | Spectrum Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01549886 Background | Nov 2011 → Jun 2014 | B-cell non-Hodgkin lymphoma | Spectrum Pharmaceuticals, Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y-90-Zevalin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01549886 ↗ |
| Known as | [90Y]- ibritumomab tiuxetan (Zevalin) | “[90Y]- ibritumomab tiuxetan (Zevalin)” NCT01549886 ↗ |
| Route | Intravenous | “Y-90-Zevalin administered by intravenous infusion.” NCT01510184 ↗ |